tiprankstipranks
Prelude Therapeutics (PRLD)
NASDAQ:PRLD
US Market

Prelude Therapeutics (PRLD) Financial Statements

99 Followers

Prelude Therapeutics Financial Overview

Prelude Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.176; its P/E ratio is -2.18; Prelude Therapeutics is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is $-0.48. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Jun 23Mar 23Dec 22Sep 22
Income Statement-
Total Revenue----$ 0.00
Gross Profit-----
EBIT$ -33.08M$ -30.43M$ -27.72M$ -28.64M$ -30.41M
EBITDA$ -33.21M$ -29.80M$ -27.45M$ -28.02M$ -30.07M
Net Income Common Stockholders$ -33.08M$ -30.43M$ -27.72M$ -28.64M$ -29.96M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 232.94M$ 254.99M$ 172.25M$ 201.73M$ 224.04M
Total Assets$ 277.67M$ 280.61M$ 198.32M$ 220.50M$ 242.33M
Total Debt$ 16.89M$ 938.00K$ 1.39M$ 1.83M$ 1.39M
Net Debt$ -216.05M$ -254.05M$ -170.87M$ -199.90M$ -222.66M
Total Liabilities$ 40.58M$ 18.55M$ 23.02M$ 25.06M$ 24.92M
Stockholders Equity$ 237.09M$ 262.06M$ 175.30M$ 195.44M$ 217.41M
Cash Flow-
Free Cash Flow$ -24.71M$ -59.59M$ -30.94M$ -23.32M$ -21.36M
Operating Cash Flow$ -23.58M$ -57.80M$ -30.13M$ -22.93M$ -20.44M
Investing Cash Flow$ 7.74M$ -57.43M$ 18.00M$ 1.35M$ 21.61M
Financing Cash Flow$ 25.24M$ 111.07M$ -269.00K$ 155.00K$ 148.00K
Currency in USD

Prelude Therapeutics Earnings and Revenue History

Prelude Therapeutics Debt to Assets

Prelude Therapeutics Cash Flow

Prelude Therapeutics Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis